Orphan disease drug developer Ultragenyx Pharmaceutical Inc. has filed a registration statement with the U.S. Securities and Exchange Commission (SEC) indicating its intent to raise $86.25 million through an initial public offering (IPO). Information about the company’s recently finalized licensing agreement with a Tokyo-based drug developer appears in Issue 64 of this Bulletin. According to a news source, Novato, California-based Ultragenyx has attracted considerable attention by moving swiftly into the orphan disease space and has several drugs moving through Phase I and II clinical trials. In its prospectus summary, the company reports that its "current pipeline consists of two product catergories: biologics, including a monoclonal antibody and enzyme replacement therapies; and small-molecule substrate replacement therapies" for use in the "treatment of rare and ultra-rare diseases." See Ultragenyx Pharmaceutical SEC Form S-1 and San Francisco Business Times, November 8, 2013.